KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$2.5 million.

  • Recursion Pharmaceuticals' Cash from Investing Activities rose 4412.54% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.8 million, marking a year-over-year increase of 155277.61%. This contributed to the annual value of $260.1 million for FY2024, which is 264261.83% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Cash from Investing Activities stood at -$2.5 million, which was up 4412.54% from -$5.8 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $275.5 million during Q4 2024, with a 5-year trough of -$193.9 million in Q3 2021.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$4.6 million (2024), whereas its average is $8.2 million.
  • In the last 5 years, Recursion Pharmaceuticals' Cash from Investing Activities tumbled by 1582820.51% in 2021 and then surged by 1117138.26% in 2024.
  • Recursion Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$52.2 million in 2021, then soared by 84.73% to -$8.0 million in 2022, then surged by 68.82% to -$2.5 million in 2023, then surged by 11171.38% to $275.5 million in 2024, then tumbled by 100.93% to -$2.5 million in 2025.
  • Its last three reported values are -$2.5 million in Q3 2025, -$5.8 million for Q2 2025, and -$7.3 million during Q1 2025.